Iron supplementation during mid-pregnancy is associated with a higher likelihood of gestational diabetes, hypertension, and metabolic syndrome, according to a study in the August issue of the American Journal of Obstetrics and Gynecology.
Iron supplementation during mid-pregnancy is associated with a higher likelihood of gestational diabetes, hypertension, and metabolic syndrome, according to a study in the August issue of the American Journal of Obstetrics and Gynecology.
Simona Bo, MD, and colleagues from the University of Turin in Italy examined the association between iron supplementation and metabolic or hypertensive abnormalities during mid-pregnancy (24-28 weeks) in 1,000 women. Of these, 500 had gestational diabetes mellitus and 212 used iron supplements.
The researchers found that iron supplement users had a higher prevalence of gestational diabetes mellitus (70.8% vs. 44.4%), hypertension (25.9% vs. 9.8%), and metabolic syndrome (25.9% vs. 10.4%). After adjusting for multiple confounders, the risk was two- to threefold higher for each condition. Women in both groups who took iron supplements had significantly higher values on the glucose tolerance test.
“Iron supplementation is associated with glucose impairment and hypertension in mid-pregnancy; its potential harmful effects might be carefully debated regarding its effectiveness,” Bo and colleagues conclude.
Bo S, Menato G, Villois P, et al. Iron supplementation and gestational diabetes in midpregnancy. Am J Obstet Gynecol. 2009;201:158.e1-6.
Single iron infusion in late pregnancy significantly reduces anemia risk
January 22nd 2025A recent study found that a single dose of intravenous iron in the third trimester is superior to oral iron in reducing anemia rates in pregnant women, ensuring better outcomes for mother and baby.
Read More
FDA grants 510(k) clearance to cobas liat STI multiplex assay panels
Published: January 22nd 2025 | Updated: January 22nd 2025The new panels, leveraging rapid polymerase chain reaction technology, allow point of care sexually transmitted infection diagnosis in 20 minutes, enhancing targeted treatment and reducing follow-up losses.
Read More